Kavanagh-Wright Lucille, Smith Thomas P, Gibney James, McKenna T Joseph
Department of Endocrinology, St Vincent's University Hospital, Elm Park, Dublin 4, Ireland.
Clin Endocrinol (Oxf). 2009 Apr;70(4):599-605. doi: 10.1111/j.1365-2265.2008.03402.x. Epub 2008 Sep 2.
It has been reported that macroprolactin is a complex of PRL and an immunoglobulin G (IgG). This study further characterizes macroprolactin and evaluates for other markers of autoimmunity using a cohort of macroprolactinaemic sera. PATIENTS AND NORMAL SUBJECTS: Following treatment of hyperprolactinaemic sera (n = 58) with polyethylene glycol (PEG), PRL values fell from 524-13 546 mU/l (Range) to 452-8455 mU/l, while in macroprolactinaemic sera (n = 41), PRL concentration fell from 525-5747 to 98-378 mU/l (PEG treated normoprolactinaemic reference range, 68-230 mU/l in males, 70-390 mU/l in females).
PRL was measured in sera prior to and following gel filtration chromatography, ultrafiltration, treatment with protein A-sepharose, protein G-sepharose, antihuman IgG-agarose and sodium thiocyanate (NaSCN). The binding of radio-labelled PRL in macroprolactinaemic sera was also measured. Sera were assayed for antithyroid and antinuclear antibodies. C-reactive protein (CRP) and CD5 positive B cells were also measured. Comparisons were made between values obtained in normal, hyperprolactinaemic and macroprolactinaemic sera. Results Macroprolactinaemic sera indicated the presence of an IgG molecule and/or IgG fragments with one or more molecules of PRL. In 97% of the sera macroprolactin had a molecular weight of 204 kDa. Treatment of macroprolactinaemic sera with NaSCN caused dissociation of macroprolactin, releasing monomeric PRL. Macroprolactinaemic sera did not yield evidence of an increase in markers of autoimmunity when compared with hyperprolactinaemic or normal sera.
Comprehensive analysis of macroprolactin confirmed its composition as an IgG molecule or fragment with a PRL molecule. The occurrence of macroprolactin does not appear to be associated with autoimmunity.
据报道,大分子催乳素是催乳素(PRL)与免疫球蛋白G(IgG)的复合物。本研究进一步对大分子催乳素进行特征分析,并使用一组大分子催乳素血症血清评估其他自身免疫标志物。患者和正常受试者:用聚乙二醇(PEG)处理高催乳素血症血清(n = 58)后,PRL值从524 - 13546 mU/l(范围)降至452 - 8455 mU/l,而在大分子催乳素血症血清(n = 41)中,PRL浓度从525 - 5747降至98 - 378 mU/l(PEG处理后的正常催乳素血症参考范围,男性为68 - 230 mU/l,女性为70 - 390 mU/l)。
在凝胶过滤色谱、超滤、用蛋白A - 琼脂糖、蛋白G - 琼脂糖、抗人IgG - 琼脂糖和硫氰酸钠(NaSCN)处理之前和之后测量血清中的PRL。还测量了大分子催乳素血症血清中放射性标记PRL的结合情况。检测血清中的抗甲状腺和抗核抗体。还测量了C反应蛋白(CRP)和CD5阳性B细胞。对正常、高催乳素血症和大分子催乳素血症血清中获得的值进行比较。结果大分子催乳素血症血清表明存在一个IgG分子和/或带有一个或多个PRL分子的IgG片段。在97%的血清中,大分子催乳素的分子量为204 kDa。用NaSCN处理大分子催乳素血症血清会导致大分子催乳素解离,释放出单体PRL。与高催乳素血症或正常血清相比,大分子催乳素血症血清未显示出自身免疫标志物增加的证据。
对大分子催乳素的综合分析证实其组成为一个带有PRL分子的IgG分子或片段。大分子催乳素的出现似乎与自身免疫无关。